The therapeutic potential of targeting the HGF/cMET axis in ovarian cancer

Moran-Jones, K. (2016) The therapeutic potential of targeting the HGF/cMET axis in ovarian cancer. Molecular Diagnosis and Therapy, 20(3), pp. 199-212. (doi: 10.1007/s40291-016-0201-8) (PMID:27139908)

118484.pdf - Accepted Version



Survival rates for ovarian cancer have remained relatively stable for the past two decades, despite advances in surgical techniques and cytotoxic chemotherapeutics, indicating a requirement for better therapies. One pathway currently proposed for targeting is the HGF/cMET pathway. Up-regulated in a number of tumour types, cMET is a tyrosine kinase receptor expressed on epithelial cells. In ovarian cancer, it has been identified as highly expressed in the four major subtypes, with expression estimates ranging from 11-68% of cases. HGF, the only known ligand for cMET, is found at high levels in both serum and ascites in women with ovarian cancer, and proposed to induce both migration and metastasis. However, clinically validated biomarkers are not yet available for either HGF or cMET, preventing a clear understanding of the true rate of over-expression, or its correlation with prognosis. Despite this, a number of agents against HGF and cMET are currently being investigated in clinical trials for multiple tumour types, including ovarian. However, a lack of patient selection, biomarker usage, and post-hoc analysis correlating response with expression, has resulted in the majority of these trials showing little beneficial effect from these agents, indicating that additional research is required to determine their usefulness in patients with ovarian cancer.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Moran-Jones, Dr Kim
Authors: Moran-Jones, K.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Molecular Diagnosis and Therapy
Publisher:Springer International Publishing
ISSN (Online):1179-2000
Published Online:30 April 2016
Copyright Holders:Copyright © 2016 Springer International Publishing Switzerland
First Published:First published in Molecular Diagnosis and Therapy 20(3):199-212
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
656911Defining Platinum and PARP Responsive Molecular Phenotypes of Pancreatic Cancer.Andrew BiankinWellcome Trust (WELLCOME)103721/Z/14/ZICS - TRANSLATIONAL RESEARCH CENTRE